Summary & Overview
CPT 1001T: Autologous Muscle Progenitor Injection into External Anal Sphincter
CPT code 1001T represents an autologous cell-based injection procedure in which a provider injects a patient’s own muscle progenitor cells into the external anal sphincter, optionally using ultrasound guidance. The code captures a novel, targeted therapy intended to improve sphincter muscle function and address disorders associated with sphincter weakness. National attention centers on this code because it documents an advanced biologic intervention that intersects specialized outpatient procedural services and emerging regenerative medicine.
This analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical and billing overview, payer coverage considerations, common coding relationships, and benchmarks where available. The publication summarizes policy updates or coverage patterns relevant to advanced regenerative procedures, provides context on typical sites of service and service type, and outlines what to expect in claims processing and documentation requirements. Clinical context explains the intended therapeutic target and procedural setting to help coding, billing, and policy teams align documentation with payer expectations.
Data not available in the input is noted where specific payer policies, modifiers, taxonomies, ICD-10 mappings, and related codes would normally be detailed.
Billing Code Overview
CPT code 1001T describes a procedure in which the provider injects the patient's own muscle progenitor cells into the external anal sphincter to improve muscle function. The description notes that the provider may use ultrasound guidance to assist the injection.
-
Service type: Autologous cell injection therapy targeting the external anal sphincter muscle
-
Typical site of service: Outpatient procedural setting such as an ambulatory surgery center or clinic procedure room where image-guided injections are performed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old female with postpartum-related fecal incontinence presents to a colorectal specialist after conservative measures (pelvic floor physical therapy, biofeedback, and continence medications) fail to improve symptoms. The evaluation includes anorectal manometry, endoanal ultrasound, and clinical exam confirming external anal sphincter weakness with preserved pudendal nerve function. The provider discusses autologous muscle progenitor cell injection into the external anal sphincter to improve sphincter contractility.
Procedure workflow: The patient arrives to an ambulatory surgical center or hospital outpatient department. After informed consent, the provider harvests a small muscle biopsy (often from the thigh) in a separate minor procedure or as part of a prior visit; muscle progenitor cells are expanded in a laboratory. On the day of injection, the patient is positioned in the lithotomy or prone jackknife position. Under local anesthesia with or without sedation, the provider uses digital guidance and may use endoanal or transperineal ultrasound for needle localization. Multiple small-volume injections of the patient’s autologous muscle progenitor cells are delivered into the external anal sphincter to augment muscle bulk and contractile function. The patient is observed briefly for immediate complications (bleeding, pain, infection) and discharged with instructions for activity modification and follow-up assessments including repeat anorectal manometry and continence scoring over months to assess functional improvement.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 |